Clinical Trial Update: Bisantrene for Relapsed /Refractory AML [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for bisantrene in relapsed/refractory acute myeloid leukemia (AML), including patients with allogeneic stem cell transplantation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• bisantrene (bisantrene)

Snippet

Sponsor: Sheba Medical Center | Conditions: Acute Myelogenous Leukemia, Allogeneic Stem Cell Transplantation | Phase 2 | Status: COMPLETED